# OnCo record paper-rockstar-blood-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rockstar-blood-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rockstar-blood-2021" ;
  schema:name "Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study"@en ;
  schema:description "The primary report of ROCKstar: about three in four patients with chronic graft-versus-host disease that had failed at least two treatments responded to belumosudil at either dose, and responses lasted about a year."@en ;
  schema:url <https://onco.cc/key-papers/paper-rockstar-blood-2021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1182/blood.2021012021>, <https://pubmed.ncbi.nlm.nih.gov/34265047/>, <https://clinicaltrials.gov/study/NCT03640481> ;
  schema:sameAs <https://doi.org/10.1182/blood.2021012021> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Cutler C, Lee SJ, Arai S, et al." ;
  onco:drugs <https://onco.cc/drugs/belumosudil/> ;
  onco:companies <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/allogeneic-transplant/> ;
  onco:trials <https://onco.cc/trials/rockstar/> ;
  onco:journals <https://onco.cc/journals/blood/> .